Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
VYLOY: renal pharmacokinetic evidence and its limits
Product / population
Adult IV VYLOY in the labeled biomarker-selected gastric/GEJ cancer setting. Partner chemotherapy has separate renal requirements.
Renal method
CLcr >=30 to <90 mL/min; not indexed eGFR
Source revision
08/2026
Retrieved
2026-11-07
Local review status
Selected named sections summarized; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
PK-only evidence must not become a universal no-adjustment rule
The reviewed renal passage is a population-PK statement with a lower studied boundary, not a complete renal dosing algorithm.
What to reconcile: Retain the CLcr metric and limits, and review companion chemotherapy independently.
DailyMed / product prescribing information · Adult IV VYLOY in the labeled biomarker-selected gastric/GEJ cancer setting. Partner chemotherapy has separate renal requirements.
Renal method: CLcr >=30 to <90 mL/min; not indexed eGFR Source date: 08/2026 Retrieved: 2026-11-07
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding
Severe impairment and dialysis dosing are not established here.
Dialysis evidence: No dialysis regimen established in selected content
Selected named sections summarized; not a complete monograph or independent clinician approval.
Section 12.3, specific populations
Population pharmacokinetics found no clinically meaningful clearance difference with CLcr at least 30 but below 90 mL/min. Severe impairment has not been characterized. This is a pharmacokinetic finding, not a stand-alone dose table or a dialysis recommendation. Apply the full VYLOY regimen and independently check the renal requirements of companion chemotherapy.
RDM71-zolbetuximab-vyloy-label-1 · Source locator: Section 12.3, specific populations
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
